Looks like you’re on the UK site. Choose another location to see content specific to your location
Lilly Buys Calytrix Bio for $1.5bn in Myelofibrosis Push
Eli Lilly has agreed to acquire Calytrix Bio in a deal worth up to $1.5bn, extending the company’s myeloproliferative neoplasms (MPN) portfolio into essential thrombocythemia and myelofibrosis. Announced on 16 November 2026, the acquisition of the JPMorgan Life Sciences Private Capital-founded Boston biotech marks Lilly’s second major MPN-focused deal of 2026 and reinforces the company’s expanding oncology M&A programme alongside continued obesity franchise momentum highlighted at ObesityWeek.
Calytrix Bio is based in Wellesley Hills, Massachusetts, and was founded in 2025 by JPMorgan Life Sciences Private Capital. The company focuses on rare, potentially life-threatening blood cancers known as myeloproliferative neoplasms, with its pipeline covering essential thrombocythemia and myelofibrosis. The acquisition follows Lilly’s April 2026 purchase of Ajax Therapeutics for up to $2.3bn, which brought a next-generation JAK inhibitor targeting myelofibrosis and polycythaemia vera into Lilly’s pipeline. The combined deals position Lilly as a major new strategic player across the broader MPN therapeutic landscape, with an expanding pipeline covering multiple MPN subtypes and mechanistic angles beyond the historically JAK inhibitor-dominated treatment paradigm. Announcement coincided with the start of the American Society of Hematology (ASH) meeting season, reinforcing the strategic timing around key haematology commercial windows.
The Calytrix acquisition forms part of Lilly’s broader Boston-based biotech acquisition programme, which has also recently included a separate deal to acquire Kelonia Therapeutics for up to $7bn. The scale and pace of Lilly’s oncology dealmaking reflects a strategic diversification push beyond the dominant obesity and metabolic franchises anchored by Mounjaro and Zepbound, with both deals demonstrating a willingness to pay substantial premiums for differentiated clinical-stage assets in oncology subcategories with significant unmet medical need. Essential thrombocythemia and myelofibrosis represent substantial addressable MPN patient populations where current therapeutic options remain limited by efficacy, tolerability or long-term disease modification. The Calytrix origin story, as a JPMorgan Life Sciences Private Capital-founded biotech reaching a $1.5bn acquisition within 18 months of launch, also underlines the pace of institutional capital formation in high-conviction oncology subcategories.
The commercial signal is a continued acceleration of Lilly’s oncology M&A programme, with myeloproliferative neoplasm category consolidation anchoring strategic diversification beyond the obesity franchise. Institutional biotech capital formation continues to produce high-value acquisition targets at remarkable pace. Expect sustained big pharma M&A activity across MPN and broader haematology therapeutics through 2027 and 2028.
For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard